Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis in Symptomatic Transthyretin Cardiomyopathy (Open-Label Extension of AG10-201)
NCT03536767Phase 2Terminated
- Sponsor
- BridgeBio Pharma
- Start
- Aug 2018
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by BridgeBio Pharma. Started Aug 2018; status: terminated.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT03536767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536767.